20 articles
Circulate Health brings its therapeutic plasma exchange protocol to the UK via a partnership with London's Reborne longevity clinic.
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
Tregzi slashes chronic graft-versus-host disease rates from 44% to 12.6%, offering new hope for stem cell transplant patients.
A novel dual CAR T-cell approach eliminated blocking antibodies in highly sensitized patients, enabling kidney transplants previously considered impossible.
The EV therapy pipeline is expanding rapidly, but standardization and clinical proof remain elusive challenges for this emerging field.
Tregzi, a personalized T cell therapy, wins FDA approval to reduce dangerous immune complications in blood cancer stem cell transplant patients.
Tectonic Therapeutic enrolls 191 patients in a global trial of TX45, a novel fusion protein targeting a deadly heart-lung condition.
Scribe Therapeutics launches first human trial of STX-1150, a reversible epigenetic therapy targeting PCSK9 to lower LDL without altering DNA.
A 20,000-person study validates IgG glycans as aging biomarkers, with therapeutic plasma exchange reducing glycan age by 0.4 years per month.
United Therapeutics wins FDA approval for LungFX, a device that keeps donor lungs viable outside the body for transplant reassessment.
CellProthera's ProtheraCytes targets heart repair post-myocardial infarction, aiming to prevent heart failure before damage becomes irreversible.
Five beta thalassemia patients no longer need regular blood transfusions after Chinese gene therapy treatment.
A case series of 18 patients found teclistamab helped most with refractory autoimmune diseases, but serious risks remain.
A randomized trial found hypothermic oxygenated perfusion slashed early graft failure rates from 37% to 20% in liver transplant patients.
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
Early data show sustained telomere lengthening in blood cells, while a new licensing deal advances a dystrophin therapy for Duchenne muscular dystrophy.
Tzield becomes the first FDA-approved disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes in pediatric patients ages 8–17.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Celularity and Fountain Life are offering an investigational cell therapy in Florida under a new state law bypassing FDA approval.
Telitacicept slashed urinary protein by 59% in 39 weeks, signaling a major advance for a kidney disease affecting millions worldwide.
